-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
-
Summary
-
NewAmsterdam Pharma Co N.V. quarterly/annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and growth rate from Q1 2023 to Q2 2024.
- NewAmsterdam Pharma Co N.V. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending June 30, 2024 was -$39M, a 1.87% decline year-over-year.
- NewAmsterdam Pharma Co N.V. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2023 was -$177M, a 1438% decline from 2022.
- NewAmsterdam Pharma Co N.V. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2022 was -$11.5M, a 72.3% increase from 2021.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Growth (%)